KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases
BACKGROUND The validity of the KRAS mutation as a predictor of recurrence‐free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection. METHODS Pa...
Gespeichert in:
| Veröffentlicht in: | Cancer 2014-12, Vol.120 (24), p.3965-3971 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3971 |
|---|---|
| container_issue | 24 |
| container_start_page | 3965 |
| container_title | Cancer |
| container_volume | 120 |
| creator | Kemeny, Nancy E. Chou, Joanne F. Capanu, Marinela Gewirtz, Alexandra N. Cercek, Andrea Kingham, T. Peter Jarnagin, William R. Fong, Yuman C. DeMatteo, Ronald P. Allen, Peter J. Shia, Jinru Ang, Celina Vakiani, Efsevia D'Angelica, Michael I. |
| description | BACKGROUND
The validity of the KRAS mutation as a predictor of recurrence‐free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection.
METHODS
Patients with resected colorectal liver metastases who received adjuvant hepatic arterial infusion plus systemic therapy and for whom KRAS data was available were evaluated. Correlation between KRAS and clinical factors was done using the Fisher exact test. Kaplan‐Meier methods were used to estimate the median RFS and OS.
RESULTS
A total of 169 patients were evaluated, 118 of whom had KRAS wild‐type (WT) and 51 had KRAS mutated (MUT) tumors. The 3‐year RFS rate was 46% for patients with KRAS WT (95% confidence interval [95% CI], 35%‐56%) and 30% (95% CI, 16%‐44%) for patients with KRAS MUT (P =.005). The 3‐year OS rate was 95% (95% CI, 87%‐98%) and 81% (95% CI, 62%‐95%), respectively, for patients with KRAS WT and KRAS MUT (P =.07). On multivariate analysis, KRAS remained a significant predictor of RFS (hazard ratio, 1.9). The 3‐year cumulative recurrence rate by site of metastases was as follows: 2% versus 13.4% for bone (P≤.01), 2% versus 14.5% for brain (P =.05), 33.2% versus 58% for lung (P≤.01), and 30% versus 47% for liver (P =.10) in patients with KRAS WT versus KRAS MUT.
CONCLUSIONS
In the current study, among patients with resected colorectal liver metastases who were treated with adjuvant hepatic arterial infusion plus systemic therapy, patients with KRAS MUT were found to have a significantly worse 3‐year RFS (30%) compared with KRAS WT (46%) p=.005. The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT. Cancer 2014;120:3965–3971. © 2014 American Cancer Society.
Among patients with resected colorectal liver metastases treated with adjuvant therapy, those with mutated KRAS appear to have significantly higher incidences of bone, brain, and lung metastases compared with patients with wild‐type KRAS. In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 26.4 months vs 14.5 months for patients with KRAS wild‐type). In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 14.5 months vs. median 26.4 months for patients with KRAS wild‐type). |
| doi_str_mv | 10.1002/cncr.28954 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4574496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1634272886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5864-d0193c0667b13b656413ab4d4af5ab5fcab6ea407119972870e4a907d5c76d183</originalsourceid><addsrcrecordid>eNp9kVtr3DAQhUVoSbZJXvIDil8KoeBUsnWxXwph6Y2GBtIW-ibG8nijIksbyW7Jv6-c3abtS2FAI82ncwYOIWeMXjBKq1fGm3hRNa3gB2TFaKtKynj1hKwopU0peP3tiDxL6Xu-qkrUh-SoEkzkUiviP95cfi7GeYLJBl9YP7gZvcFURDRzjEtfbGGaMPqUx0tv0U-pmH2PcROs3xS3uLya_CWhedAJQ2GCC1ljAleMOEHKhemEPB3AJTzdn8fk69s3X9bvy6vrdx_Wl1elEY3kZU9ZWxsqpepY3UkhOauh4z2HQUAnBgOdROBUMda2qmoURQ4tVb0wSvasqY_J653udu5G7E3eOILT22hHiPc6gNX_Try91ZvwQ3OhOG9lFjjfC8RwN2Oa9GiTQefAY5iTZrLmVXZuFvTlDjUxpBRxeLRhVC8B6SUg_RBQhp__vdgj-juRDLzYA5AMuCGCNzb94VoqsqvIHNtxP63D-_9Y6vWn9c3O_Bdl56ul</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634272886</pqid></control><display><type>article</type><title>KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Kemeny, Nancy E. ; Chou, Joanne F. ; Capanu, Marinela ; Gewirtz, Alexandra N. ; Cercek, Andrea ; Kingham, T. Peter ; Jarnagin, William R. ; Fong, Yuman C. ; DeMatteo, Ronald P. ; Allen, Peter J. ; Shia, Jinru ; Ang, Celina ; Vakiani, Efsevia ; D'Angelica, Michael I.</creator><creatorcontrib>Kemeny, Nancy E. ; Chou, Joanne F. ; Capanu, Marinela ; Gewirtz, Alexandra N. ; Cercek, Andrea ; Kingham, T. Peter ; Jarnagin, William R. ; Fong, Yuman C. ; DeMatteo, Ronald P. ; Allen, Peter J. ; Shia, Jinru ; Ang, Celina ; Vakiani, Efsevia ; D'Angelica, Michael I.</creatorcontrib><description>BACKGROUND
The validity of the KRAS mutation as a predictor of recurrence‐free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection.
METHODS
Patients with resected colorectal liver metastases who received adjuvant hepatic arterial infusion plus systemic therapy and for whom KRAS data was available were evaluated. Correlation between KRAS and clinical factors was done using the Fisher exact test. Kaplan‐Meier methods were used to estimate the median RFS and OS.
RESULTS
A total of 169 patients were evaluated, 118 of whom had KRAS wild‐type (WT) and 51 had KRAS mutated (MUT) tumors. The 3‐year RFS rate was 46% for patients with KRAS WT (95% confidence interval [95% CI], 35%‐56%) and 30% (95% CI, 16%‐44%) for patients with KRAS MUT (P =.005). The 3‐year OS rate was 95% (95% CI, 87%‐98%) and 81% (95% CI, 62%‐95%), respectively, for patients with KRAS WT and KRAS MUT (P =.07). On multivariate analysis, KRAS remained a significant predictor of RFS (hazard ratio, 1.9). The 3‐year cumulative recurrence rate by site of metastases was as follows: 2% versus 13.4% for bone (P≤.01), 2% versus 14.5% for brain (P =.05), 33.2% versus 58% for lung (P≤.01), and 30% versus 47% for liver (P =.10) in patients with KRAS WT versus KRAS MUT.
CONCLUSIONS
In the current study, among patients with resected colorectal liver metastases who were treated with adjuvant hepatic arterial infusion plus systemic therapy, patients with KRAS MUT were found to have a significantly worse 3‐year RFS (30%) compared with KRAS WT (46%) p=.005. The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT. Cancer 2014;120:3965–3971. © 2014 American Cancer Society.
Among patients with resected colorectal liver metastases treated with adjuvant therapy, those with mutated KRAS appear to have significantly higher incidences of bone, brain, and lung metastases compared with patients with wild‐type KRAS. In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 26.4 months vs 14.5 months for patients with KRAS wild‐type). In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 14.5 months vs. median 26.4 months for patients with KRAS wild‐type).</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.28954</identifier><identifier>PMID: 25155157</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley-Blackwell</publisher><subject>adjuvant therapy ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; colorectal cancer ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; disease recurrence patterns ; Disease-Free Survival ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatectomy ; Humans ; KRAS mutation ; liver metastases ; Liver Neoplasms - mortality ; Liver Neoplasms - secondary ; Liver Neoplasms - surgery ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Mutation ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - genetics ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Tumors</subject><ispartof>Cancer, 2014-12, Vol.120 (24), p.3965-3971</ispartof><rights>2014 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>2014 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5864-d0193c0667b13b656413ab4d4af5ab5fcab6ea407119972870e4a907d5c76d183</citedby><cites>FETCH-LOGICAL-c5864-d0193c0667b13b656413ab4d4af5ab5fcab6ea407119972870e4a907d5c76d183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.28954$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.28954$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,781,785,886,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=29052885$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25155157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kemeny, Nancy E.</creatorcontrib><creatorcontrib>Chou, Joanne F.</creatorcontrib><creatorcontrib>Capanu, Marinela</creatorcontrib><creatorcontrib>Gewirtz, Alexandra N.</creatorcontrib><creatorcontrib>Cercek, Andrea</creatorcontrib><creatorcontrib>Kingham, T. Peter</creatorcontrib><creatorcontrib>Jarnagin, William R.</creatorcontrib><creatorcontrib>Fong, Yuman C.</creatorcontrib><creatorcontrib>DeMatteo, Ronald P.</creatorcontrib><creatorcontrib>Allen, Peter J.</creatorcontrib><creatorcontrib>Shia, Jinru</creatorcontrib><creatorcontrib>Ang, Celina</creatorcontrib><creatorcontrib>Vakiani, Efsevia</creatorcontrib><creatorcontrib>D'Angelica, Michael I.</creatorcontrib><title>KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
The validity of the KRAS mutation as a predictor of recurrence‐free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection.
METHODS
Patients with resected colorectal liver metastases who received adjuvant hepatic arterial infusion plus systemic therapy and for whom KRAS data was available were evaluated. Correlation between KRAS and clinical factors was done using the Fisher exact test. Kaplan‐Meier methods were used to estimate the median RFS and OS.
RESULTS
A total of 169 patients were evaluated, 118 of whom had KRAS wild‐type (WT) and 51 had KRAS mutated (MUT) tumors. The 3‐year RFS rate was 46% for patients with KRAS WT (95% confidence interval [95% CI], 35%‐56%) and 30% (95% CI, 16%‐44%) for patients with KRAS MUT (P =.005). The 3‐year OS rate was 95% (95% CI, 87%‐98%) and 81% (95% CI, 62%‐95%), respectively, for patients with KRAS WT and KRAS MUT (P =.07). On multivariate analysis, KRAS remained a significant predictor of RFS (hazard ratio, 1.9). The 3‐year cumulative recurrence rate by site of metastases was as follows: 2% versus 13.4% for bone (P≤.01), 2% versus 14.5% for brain (P =.05), 33.2% versus 58% for lung (P≤.01), and 30% versus 47% for liver (P =.10) in patients with KRAS WT versus KRAS MUT.
CONCLUSIONS
In the current study, among patients with resected colorectal liver metastases who were treated with adjuvant hepatic arterial infusion plus systemic therapy, patients with KRAS MUT were found to have a significantly worse 3‐year RFS (30%) compared with KRAS WT (46%) p=.005. The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT. Cancer 2014;120:3965–3971. © 2014 American Cancer Society.
Among patients with resected colorectal liver metastases treated with adjuvant therapy, those with mutated KRAS appear to have significantly higher incidences of bone, brain, and lung metastases compared with patients with wild‐type KRAS. In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 26.4 months vs 14.5 months for patients with KRAS wild‐type). In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 14.5 months vs. median 26.4 months for patients with KRAS wild‐type).</description><subject>adjuvant therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>colorectal cancer</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>disease recurrence patterns</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatectomy</subject><subject>Humans</subject><subject>KRAS mutation</subject><subject>liver metastases</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Mutation</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kVtr3DAQhUVoSbZJXvIDil8KoeBUsnWxXwph6Y2GBtIW-ibG8nijIksbyW7Jv6-c3abtS2FAI82ncwYOIWeMXjBKq1fGm3hRNa3gB2TFaKtKynj1hKwopU0peP3tiDxL6Xu-qkrUh-SoEkzkUiviP95cfi7GeYLJBl9YP7gZvcFURDRzjEtfbGGaMPqUx0tv0U-pmH2PcROs3xS3uLya_CWhedAJQ2GCC1ljAleMOEHKhemEPB3AJTzdn8fk69s3X9bvy6vrdx_Wl1elEY3kZU9ZWxsqpepY3UkhOauh4z2HQUAnBgOdROBUMda2qmoURQ4tVb0wSvasqY_J653udu5G7E3eOILT22hHiPc6gNX_Try91ZvwQ3OhOG9lFjjfC8RwN2Oa9GiTQefAY5iTZrLmVXZuFvTlDjUxpBRxeLRhVC8B6SUg_RBQhp__vdgj-juRDLzYA5AMuCGCNzb94VoqsqvIHNtxP63D-_9Y6vWn9c3O_Bdl56ul</recordid><startdate>20141215</startdate><enddate>20141215</enddate><creator>Kemeny, Nancy E.</creator><creator>Chou, Joanne F.</creator><creator>Capanu, Marinela</creator><creator>Gewirtz, Alexandra N.</creator><creator>Cercek, Andrea</creator><creator>Kingham, T. Peter</creator><creator>Jarnagin, William R.</creator><creator>Fong, Yuman C.</creator><creator>DeMatteo, Ronald P.</creator><creator>Allen, Peter J.</creator><creator>Shia, Jinru</creator><creator>Ang, Celina</creator><creator>Vakiani, Efsevia</creator><creator>D'Angelica, Michael I.</creator><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141215</creationdate><title>KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases</title><author>Kemeny, Nancy E. ; Chou, Joanne F. ; Capanu, Marinela ; Gewirtz, Alexandra N. ; Cercek, Andrea ; Kingham, T. Peter ; Jarnagin, William R. ; Fong, Yuman C. ; DeMatteo, Ronald P. ; Allen, Peter J. ; Shia, Jinru ; Ang, Celina ; Vakiani, Efsevia ; D'Angelica, Michael I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5864-d0193c0667b13b656413ab4d4af5ab5fcab6ea407119972870e4a907d5c76d183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>adjuvant therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>colorectal cancer</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>disease recurrence patterns</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatectomy</topic><topic>Humans</topic><topic>KRAS mutation</topic><topic>liver metastases</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Mutation</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kemeny, Nancy E.</creatorcontrib><creatorcontrib>Chou, Joanne F.</creatorcontrib><creatorcontrib>Capanu, Marinela</creatorcontrib><creatorcontrib>Gewirtz, Alexandra N.</creatorcontrib><creatorcontrib>Cercek, Andrea</creatorcontrib><creatorcontrib>Kingham, T. Peter</creatorcontrib><creatorcontrib>Jarnagin, William R.</creatorcontrib><creatorcontrib>Fong, Yuman C.</creatorcontrib><creatorcontrib>DeMatteo, Ronald P.</creatorcontrib><creatorcontrib>Allen, Peter J.</creatorcontrib><creatorcontrib>Shia, Jinru</creatorcontrib><creatorcontrib>Ang, Celina</creatorcontrib><creatorcontrib>Vakiani, Efsevia</creatorcontrib><creatorcontrib>D'Angelica, Michael I.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kemeny, Nancy E.</au><au>Chou, Joanne F.</au><au>Capanu, Marinela</au><au>Gewirtz, Alexandra N.</au><au>Cercek, Andrea</au><au>Kingham, T. Peter</au><au>Jarnagin, William R.</au><au>Fong, Yuman C.</au><au>DeMatteo, Ronald P.</au><au>Allen, Peter J.</au><au>Shia, Jinru</au><au>Ang, Celina</au><au>Vakiani, Efsevia</au><au>D'Angelica, Michael I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2014-12-15</date><risdate>2014</risdate><volume>120</volume><issue>24</issue><spage>3965</spage><epage>3971</epage><pages>3965-3971</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
The validity of the KRAS mutation as a predictor of recurrence‐free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection.
METHODS
Patients with resected colorectal liver metastases who received adjuvant hepatic arterial infusion plus systemic therapy and for whom KRAS data was available were evaluated. Correlation between KRAS and clinical factors was done using the Fisher exact test. Kaplan‐Meier methods were used to estimate the median RFS and OS.
RESULTS
A total of 169 patients were evaluated, 118 of whom had KRAS wild‐type (WT) and 51 had KRAS mutated (MUT) tumors. The 3‐year RFS rate was 46% for patients with KRAS WT (95% confidence interval [95% CI], 35%‐56%) and 30% (95% CI, 16%‐44%) for patients with KRAS MUT (P =.005). The 3‐year OS rate was 95% (95% CI, 87%‐98%) and 81% (95% CI, 62%‐95%), respectively, for patients with KRAS WT and KRAS MUT (P =.07). On multivariate analysis, KRAS remained a significant predictor of RFS (hazard ratio, 1.9). The 3‐year cumulative recurrence rate by site of metastases was as follows: 2% versus 13.4% for bone (P≤.01), 2% versus 14.5% for brain (P =.05), 33.2% versus 58% for lung (P≤.01), and 30% versus 47% for liver (P =.10) in patients with KRAS WT versus KRAS MUT.
CONCLUSIONS
In the current study, among patients with resected colorectal liver metastases who were treated with adjuvant hepatic arterial infusion plus systemic therapy, patients with KRAS MUT were found to have a significantly worse 3‐year RFS (30%) compared with KRAS WT (46%) p=.005. The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT. Cancer 2014;120:3965–3971. © 2014 American Cancer Society.
Among patients with resected colorectal liver metastases treated with adjuvant therapy, those with mutated KRAS appear to have significantly higher incidences of bone, brain, and lung metastases compared with patients with wild‐type KRAS. In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 26.4 months vs 14.5 months for patients with KRAS wild‐type). In addition, KRAS‐mutated patients had a worse recurrence‐free survival (median, 14.5 months vs. median 26.4 months for patients with KRAS wild‐type).</abstract><cop>Hoboken, NJ</cop><pub>Wiley-Blackwell</pub><pmid>25155157</pmid><doi>10.1002/cncr.28954</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2014-12, Vol.120 (24), p.3965-3971 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4574496 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | adjuvant therapy Adult Aged Aged, 80 and over Biological and medical sciences colorectal cancer Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology disease recurrence patterns Disease-Free Survival Female Gastroenterology. Liver. Pancreas. Abdomen Hepatectomy Humans KRAS mutation liver metastases Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - surgery Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Neoplasm Metastasis Neoplasm Recurrence, Local - genetics Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Tumors |
| title | KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KRAS%20mutation%20influences%20recurrence%20patterns%20in%20patients%20undergoing%20hepatic%20resection%20of%20colorectal%20metastases&rft.jtitle=Cancer&rft.au=Kemeny,%20Nancy%20E.&rft.date=2014-12-15&rft.volume=120&rft.issue=24&rft.spage=3965&rft.epage=3971&rft.pages=3965-3971&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.28954&rft_dat=%3Cproquest_pubme%3E1634272886%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1634272886&rft_id=info:pmid/25155157&rfr_iscdi=true |